Log in to save to my catalogue

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_umu_134475

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

About this item

Full title

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2016-12, Vol.375 (23), p.2246-2254

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In patients with renal-cell carcinoma at high risk for relapse after nephrectomy, the rate of disease-free survival was significantly higher among those receiving sunitinib than among those receiving placebo, at the cost of a higher rate of toxic events.
Each year, approximately 300,000 persons worldwide are diagnosed with renal-cell carcinoma,...

Alternative Titles

Full title

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_DiVA_org_umu_134475

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_umu_134475

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1611406

How to access this item